Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and Silybin-phytosome in EGFR Mutant Lung Adenocarcinoma
NCT02146118Phase 2Unknown
- Sponsor
- Medicalogic
- Start
- Apr 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of silibinin in lung adenocarcinoma, sponsored by Medicalogic. Primary endpoint: Tumour Response Rate at 12 months. Status: unknown.
02
Drugs
silibinin
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02146118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02146118.